Literature DB >> 17561563

Spread of extensively drug-resistant tuberculosis.

Sofia Samper, Carlos Martín.   

Abstract

Entities:  

Mesh:

Year:  2007        PMID: 17561563      PMCID: PMC2725978          DOI: 10.3201/eid1304.061329

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: An emergency has been declared in KwaZulu Natal, South Africa, where an outbreak of 53 cases of a highly lethal form of tuberculosis (TB) has occurred (,). This outbreak was caused by an extensively drug-resistant TB (XDR TB) strain. XDR TB is defined as TB caused by Mycobacterium tuberculosis isolates resistant to isoniazid and rifampicin plus any fluoroquinolone and ≥1 of the 3 injectable second-line drugs (). XDR TB may be considered an emerging disease but not a new disease. Nosocomial outbreaks of multidrug-resistant TB (MDR TB) occurred in Spain at the height of the HIV epidemic, when 49 TB cases were reported in an HIV ward in Madrid from 1991 through 1995 (,). Molecular epidemiology found that a particular strain caused 16 cases in another hospital in Madrid in 1993–1995 () and 31 cases in a hospital in Malaga in 1995–1998 (,). In total, 22 hospitals from 6 different regions of Spain were affected by this outbreak, which included at least 114 cases, caused by an M. bovis XDR strain (B strain) belonging to the M. tuberculosis complex. The patients included 1 from the Netherlands () and another from Canada (). The strain responsible for the 1991–1995 outbreak in Spain fits the XDR TB case definition; it was resistant to the 5 first-line drugs, as well as to ofloxacin, aminosalicylic acid, cycloserine, ethionamide, capreomycin, amikacin, and clarithromycin. Isolates were tested for drug susceptibility by the Canetti method on Lowenstein-Jensen medium supplemented with isoniazid, rifampicin, ethambutol, streptomycin, amikacin, and pyrazinamide (). The isolates were also tested on 7H10 Middlebrook agar for susceptibility to aminosalicylic acid, ethionamide, capreomycin, clarithromycin, and ofloxacin (). No effective medical treatment was available for these patients. In 2 of the hospitals affected, all patients died, with a short survival time (median of 44 and 49.5 days for the 2 hospitals) between diagnosis and death (,). A high rate of reinfection (45%) also was noted among HIV-positive patients treated with anti-TB drugs (). As a result of this outbreak, Spanish hospitals now implement exhaustive control measures, such as maintaining respiratory isolation units under negative pressure; in addition, a national surveillance network for MDR TB was set up in Spain in 1998. From 1998 through 2003, we detected 22 new cases of infection with this strain (), but no new cases have since been reported to the national MDR TB database. Our experience indicates that the implementation of more stringent control measures and the use of new, more effective treatments for HIV infection can help to bring XDR TB outbreaks under control in developed countries. However, the outlook is bleak for developing countries like South Africa, in which coinfection with HIV and a highly transmissible and untreatable XDR TB strain could amplify the TB problem to levels unprecedented since the advent of antimicrobial drugs. These countries urgently require assistance with the establishment of control measures and the development of new drugs and effective vaccines against TB.
  9 in total

1.  Transcontinental spread of multidrug-resistant Mycobacterium bovis.

Authors:  R Long; E Nobert; S Chomyc; J van Embden; C McNamee; R R Duran; J Talbot; A Fanning
Journal:  Am J Respir Crit Care Med       Date:  1999-06       Impact factor: 21.405

2.  Transmission between HIV-infected patients of multidrug-resistant tuberculosis caused by Mycobacterium bovis.

Authors:  S Samper; C Martín; A Pinedo; A Rivero; J Blázquez; F Baquero; D van Soolingen; J van Embden
Journal:  AIDS       Date:  1997-08       Impact factor: 4.177

3.  Systematic molecular characterization of multidrug-resistant Mycobacterium tuberculosis complex isolates from Spain.

Authors:  S Samper; M J Iglesias; M J Rabanaque; L I Gómez; M C Lafoz; M S Jiménez; A Ortega; M A Lezcano; D Van Soolingen; C Martín
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

4.  Infectious disease. Extensively drug-resistant TB gets foothold in South Africa.

Authors:  Jon Cohen
Journal:  Science       Date:  2006-09-15       Impact factor: 47.728

5.  Multidrug-resistant tuberculosis outbreak on an HIV ward--Madrid, Spain, 1991-1995.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1996-04-26       Impact factor: 17.586

6.  Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection.

Authors:  A Guerrero; J Cobo; J Fortún; E Navas; C Quereda; A Asensio; J Cañón; J Blazquez; E Gómez-Mampaso
Journal:  Lancet       Date:  1997-12-13       Impact factor: 79.321

7.  High rate of tuberculosis reinfection during a nosocomial outbreak of multidrug-resistant tuberculosis caused by Mycobacterium bovis strain B.

Authors:  A Rivero; M Márquez; J Santos; A Pinedo; M A Sánchez; A Esteve; S Samper; C Martín
Journal:  Clin Infect Dis       Date:  2000-12-11       Impact factor: 9.079

8.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.

Authors:  Neel R Gandhi; Anthony Moll; A Willem Sturm; Robert Pawinski; Thiloshini Govender; Umesh Lalloo; Kimberly Zeller; Jason Andrews; Gerald Friedland
Journal:  Lancet       Date:  2006-11-04       Impact factor: 79.321

9.  Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in Spain.

Authors:  J V Rullán; D Herrera; R Cano; V Moreno; P Godoy; E F Peiró; J Castell; C Ibañez; A Ortega; L S Agudo; F Pozo
Journal:  Emerg Infect Dis       Date:  1996 Apr-Jun       Impact factor: 6.883

  9 in total
  6 in total

1.  Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.

Authors:  Santiago Ramón-García; Carlos Martín; Charles J Thompson; José A Aínsa
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

Review 2.  The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: part I: the origins and nature of the problem.

Authors:  Jerrold J Ellner
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

Review 3.  An official ATS workshop report: Emerging issues and current controversies in HIV-associated pulmonary diseases.

Authors:  Alison Morris; Kristina Crothers; James M Beck; Laurence Huang
Journal:  Proc Am Thorac Soc       Date:  2011-03

4.  Four decades of transmission of a multidrug-resistant Mycobacterium tuberculosis outbreak strain.

Authors:  Vegard Eldholm; Johana Monteserin; Adrien Rieux; Beatriz Lopez; Benjamin Sobkowiak; Viviana Ritacco; Francois Balloux
Journal:  Nat Commun       Date:  2015-05-11       Impact factor: 14.919

5.  Unsuspected and extensive transmission of a drug-susceptible Mycobacterium tuberculosis strain.

Authors:  Ana Isabel López-Calleja; Patricia Gavín; Ma Antonia Lezcano; Ma Asunción Vitoria; Ma José Iglesias; Joaquín Guimbao; Ma Angeles Lázaro; Nalin Rastogi; Ma José Revillo; Carlos Martín; Sofia Samper
Journal:  BMC Pulm Med       Date:  2009-01-14       Impact factor: 3.317

6.  New insights into the transposition mechanisms of IS6110 and its dynamic distribution between Mycobacterium tuberculosis Complex lineages.

Authors:  Jesús Gonzalo-Asensio; Irene Pérez; Nacho Aguiló; Santiago Uranga; Ana Picó; Carlos Lampreave; Alberto Cebollada; Isabel Otal; Sofía Samper; Carlos Martín
Journal:  PLoS Genet       Date:  2018-04-12       Impact factor: 5.917

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.